There will be a change in the ER Drug Screen performed by the BGH lab. The changes will result in the BGH ER Drug screen being similar to the WMH urine drug screen.
The changes include:
1. Addition of a urine creatinine to the panel. This will help identify specimens that may be adulterated.
2. Removal of PCP from the panel. Currently PCP is not on the WMH panel and there has not been a positive patient PCP result in 2012 at BGH.
3. The panel will be assayed on the chemistry analyzer and should result in a shorter TAT.
4. The cutoff for benzodiazepine and barbiturates will decrease from 300ng/ml to 200ng/ml. This will agree with the cutoff at WMH.
For any questions, please contact Rosemary Parkinson, BGH Lab Supervisor at 762-2370.